Original Research Article

CNS Drugs

, Volume 23, Issue 7, pp 615-625

The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Multicentre Study
  • Esther GarciaAffiliated withLaboratorios Almirall SA
  • , Marta RobertAffiliated withLaboratorios Almirall SA
  • , Francesc PerisAffiliated withLaboratorios Almirall SA
  • , Hiroshi NakamuraAffiliated withDrug Development Division, Dainippon Sumitomo Pharma Co., Ltd Email author 
  • , Noriko SatoAffiliated withDrug Development Division, Dainippon Sumitomo Pharma Co., Ltd
  • , Yoshikatsu TerazawaAffiliated withDrug Development Division, Dainippon Sumitomo Pharma Co., Ltd

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Background: Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 and serotonin 5-HT2 antagonist properties. It may potentially have a lower incidence of adverse events than other antipsychotic agents.

Objective: To determine the efficacy and safety of three doses of blonanserin compared with placebo and haloperidol in patients with acute-phase schizophrenia.

Methods: This was a 6-week, randomized, double-blind, placebo- and haloperidol-controlled, international, multicentre study. Patients with an acute exacerbation of their schizophrenia, with a Positive and Negative Syndrome Scale (PANSS) score ≥70 and a Clinical Global Impression — Severity of Illness (CGI-S) score ≥4 (‘moderately ill’) [with no decrease ≥20% or ≥1 point, respectively, during the wash-out period] were randomized into one of five treatment groups (blonanserin 2.5, 5 or 10 mg, haloperidol 10 mg or placebo once daily). Patients were assessed weekly for clinical efficacy, adverse events, extrapyramidal symptoms (EPS) and drug compliance, and were assessed biweekly for other safety variables.

Results: All 307 randomized patients received at least one dose of study medication and 228 (74.3%) completed the study. The mean reduction in PANSS total score at week 6 was significantly greater with all active treatments compared with placebo (−12.58; p<0.001); blonanserin 10mg was significantly superior to blonanserin 2.5 mg (−30.18 vs −20.6; p<0.001), but blonanserin 5 mg (−27.19) and haloperidol 10 mg (−28.16) were not. All active treatments showed greater efficacy against the positive symptoms of schizophrenia, and blonanserin (5 and 10 mg) was more effective against the negative symptoms than haloperidol.

Blonanserin was well tolerated at all doses and there was no evidence of clinically important weight gain, orthostatic hypotension, corrected QT interval prolongation or clinically relevant changes in laboratory test results. Haloperidol caused persistent elevation in prolactin levels, but this was not seen with any dose of blonanserin throughout the study period. There was a lower incidence of EPS with blonanserin 10 mg (26.6%) than with haloperidol 10 mg (53.3%).

Conclusion: Blonanserin was effective in the treatment of acute schizophrenia and showed greater efficacy in negative symptoms compared with placebo and haloperidol. Blonanserin was well tolerated and its safety profile compared favourably with haloperidol, particularly with respect to prolactin elevation and EPS frequency.